Cargando…
Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
The outbreak of COVID-19 in Wuhan, China and its declaration as a global pandemic by WHO has left the medical community under significant pressure to rapidly identify effective therapeutic and preventative strategies. Chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) were found to be effica...
Autores principales: | Stevenson, Alex, Kirresh, Ali, Conway, Samuel, White, Laura, Ahmad, Mahmood, Little, Callum |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440188/ https://www.ncbi.nlm.nih.gov/pubmed/32817375 http://dx.doi.org/10.1136/openhrt-2020-001362 |
Ejemplares similares
-
Main operating room deliveries for patients with high-risk cardiovascular disease
por: Albright, Catherine M, et al.
Publicado: (2023) -
Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study
por: Nikiphorou, Elena, et al.
Publicado: (2020) -
Sympathetic autonomic dysfunction and impaired cardiovascular performance in higher risk surgical patients: implications for perioperative sympatholysis
por: Whittle, John, et al.
Publicado: (2015) -
Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns Study
por: Arnott, Clare, et al.
Publicado: (2015) -
Cardiovascular disease in HIV patients: from bench to bedside and backwards
por: Cerrato, Enrico, et al.
Publicado: (2015)